Improving screening for hypertrophic cardiomyopathy using advanced technology
Official title: A multi-modal approach for efficient, point-of-care screening of hypertrophic cardiomyopathy
Funded at Yale University · NIH-11031296 · Data updated 2026-11-12
This study is working on a new way to help doctors quickly and accurately spot hypertrophic cardiomyopathy (HCM) using smart technology and wearable devices, making it easier for everyone to get checked for this heart condition.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project start | September 1, 2023 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $86,392 |
| NIH project number | 5F32HL170592-02 |
| Project ID | NIH-11031296 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who may be at risk for hypertrophic cardiomyopathy, including those with a family history of the condition or presenting with relevant symptoms.
✕Less likely to help
Patients who have already been diagnosed with hypertrophic cardiomyopathy or those without any risk factors for the condition may not benefit from this research.
What this research studies
This research focuses on enhancing the screening process for hypertrophic cardiomyopathy (HCM), a common inherited heart condition. By utilizing advanced computational methods and wearable technology, the project aims to develop machine learning algorithms that can efficiently detect HCM at point-of-care settings. The approach includes adapting electrocardiographic signals from wearable devices and processing echocardiographic videos to improve diagnostic accuracy. This innovative method seeks to make HCM screening more accessible and effective for the general population.
Why it matters
Potential benefit: If successful, this research could lead to earlier and more accurate detection of hypertrophic cardiomyopathy, potentially reducing morbidity and mortality associated with the condition.
How similar studies have gone: Other research has shown promise in using machine learning and wearable technology for cardiovascular screening, indicating that this approach could be effective.
Where this research is happening
-
Yale University
New Haven, United States Active
Researchers
- Principal investigator: Oikonomou, Evangelos — Yale University
- Study coordinator: Oikonomou, Evangelos
Related research
Other NIH-funded projects on the same topics.
-
SGLT inhibitors for non-obstructive hypertrophic cardiomyopathy
A testing of a diabetes drug class (SGLT2 inhibitors) to help people with non-obstructive hypertrophic cardiomyopathy feel better and reduce heart-related problems.
-
Using big biobanks to understand rare gene changes in hypertrophic cardiomyopathy
A large study will look at genetic data and health information from many people to better understand how rare gene changes influence hypertrophic cardiomyopathy and its risks.
-
Understanding heart disease in hypertrophic cardiomyopathy through heart tissue and blood analysis
Researchers are studying people with hypertrophic cardiomyopathy to see how genes and signaling in heart tissue and blood relate to disease progression and risk of serious heart problems.
-
Myosin binding protein C variants and heart disease
A doctor-scientist at the University of Michigan is studying how certain genetic changes in a heart protein (MYBPC3) cause hypertrophic cardiomyopathy and whether fixing the protein or its interactions could help people with this condition.
-
MEK inhibitor for severe infantile heart failure in Noonan and related RASopathies
A 12-month, multi-site trial tests whether the medicine trametinib can help infants with life-threatening heart failure due to Noonan syndrome and related genetic conditions.
-
MEK inhibitor shows promise for serious infant heart disease in Noonan/RASopathies
A multi-site study tests whether the drug trametinib can help infants with severe heart muscle thickening caused by Noonan syndrome and related RASopathies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.